Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION440 in MECP2 Duplication Syndrome
NCT06430385Phase 2Recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 2 trial of ION440 in MECP2 duplication syndrome (M2DS), sponsored by Ionis Pharmaceuticals. Started Oct 2024; status: recruiting.
02
Drugs
ION440
03
Conditions
MECP2 duplication syndrome (M2DS)
Beyond the preview
Go deeper on NCT06430385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430385.